Opzelura, with the active ingredient ruxolitinib, is a medication approved for the topical treatment of certain skin conditions. It is a Janus kinase (JAK) inhibitor, working by blocking the signaling pathways that contribute to inflammation and skin cell growth [1].
What conditions can Opzelura treat?
Opzelura is FDA-approved for two primary indications. It is used for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older [1]. It is also indicated for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older when applied topically to affected areas [1].
How does Opzelura work for vitiligo?
In nonsegmental vitiligo, Opzelura is thought to help restore skin color by reducing inflammation associated with the condition and potentially re-pigmenting the skin [1]. Clinical trials showed that a significant percentage of patients experienced repigmentation of their facial and non-facial vitiligo lesions after treatment [1].
What is the difference between Opzelura and oral JAK inhibitors?
Opzelura is a topical formulation, meaning it is applied directly to the skin. This contrasts with oral JAK inhibitors, which are taken by mouth and work systemically throughout the body. The topical application of Opzelura aims to deliver the medication directly to the affected skin areas, potentially reducing systemic exposure and associated risks [1].
What are the common side effects of Opzelura?
The most common side effects reported in clinical trials for Opzelura include upper respiratory tract infections, acne, itching, headache, and diarrhea [1]. More serious potential side effects, although less common, include an increased risk of infections, blood clots, serious cardiovascular events, and certain types of cancer [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
When can I expect to see results with Opzelura for vitiligo?
Results for vitiligo can vary. In clinical studies, some patients began to see repigmentation within 24 weeks of treatment, with further improvement seen with continued use [1].
Can Opzelura be used long-term?
Opzelura is indicated for short-term and non-continuous chronic treatment for atopic dermatitis [1]. For vitiligo, the duration of treatment is typically guided by clinical response and physician recommendation [1].
What is the patent status for Opzelura?
Drug patent information for Opzelura, including its active ingredient ruxolitinib, is available through resources like DrugPatentWatch.com [2]. Patents for medications are crucial for the exclusivity period granted to the innovator company. Understanding these patents helps predict when generic versions might become available.
Who manufactures Opzelura?
Opzelura is manufactured by Incyte Corporation [1].